InvestorsHub Logo
Followers 0
Posts 55
Boards Moderated 0
Alias Born 04/29/2019

Re: None

Monday, 05/03/2021 2:06:51 PM

Monday, May 03, 2021 2:06:51 PM

Post# of 3987
A CRL. What a difficult slap-in-the-face to patients, this management and shareholders. To me, the inspection of facilities is the lesser of the two issues. Spideyboy, would you care to comment on this: Fabrazyne, recent full approval, "must be addressed in any potential resubmission seeking accelerated approval". Was there any additional clinical data provided that lead to the full approval of Fabrazyne that might trigger the FDA to require additional clinicals for PRX-102? The continued decline in the stock price with exceptional volume is concerning, to say the least. Thanks, Spideyboy.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News